XNCR - Xencor's tidutamab shows acceptable safety profile in early-stage study

Xencor ([[XNCR]] -3.9%) announces safety data from 27 subjects in an ongoing Phase 1 study of evaluating tidutamab (XmAb18087), an SSTR2 x CD3 bispecific antibody, in patients with neuroendocrine tumors (NETs). The results were presented at the North American Neuroendocrine Tumor Society symposium.Tidutamab was generally well-tolerated at the recommended dose for the expansion part of the trial (0.3 mcg/kg priming dose and subsequent 1.0 mcg/kg repeated doses).The most common treatment-related Grade 3 (serious) or Grade 4 (life-threatening) adverse events across all doses were lymphopenia (41%), gamma-glutamyl transferase increases (19%), vomiting (19%), transaminase increases (19%) and nausea (15%). Dose-limiting toxicities of nausea and vomiting were observed in the 1.0/2.0 mcg/kg cohort. Cytokine release syndrome ((CRS)) was observed in 41% of patients and was limited to Grade 1 and Grade 2 and also to the first two doses.Tidutamab is a bispecific antibody that binds to two proteins called somatostatin receptor subtype 2 (SSTR2) and

For further details see:

Xencor's tidutamab shows acceptable safety profile in early-stage study